XS-03 plus chemotherapy and bevacizumab for metastatic colorectal cancer with RAS mutation
Part of Cancer, Digestive system clinical trials.
This trial tests an experimental drug called XS-03 combined with standard chemotherapy (FOLFOX or FOLFIRI) plus a targeted therapy (bevacizumab) for people with metastatic colorectal cancer that has a RAS mutation. The goal is to see if adding XS-03 helps shrink tumors or slows cancer growth better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have metastatic colorectal cancer that cannot be removed by surgery.
- You must have a RAS gene mutation (a lab test can confirm this).
- If you've had prior treatment, you need either at least one prior systemic therapy (for Stage Ib) or no prior therapy (for Stage II).
- You need to be in generally good health (able to do light activity, with adequate organ function).
- You cannot have had Avastin (bevacizumab) before, for the phase II part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs (an immunotherapy called QL1706 plus bevacizumab and standard chemotherapy) as a first-line treatment for people with advanced colorectal cancer that has a BRAF V600E mutation. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests two different drug combinations for people with advanced bowel cancer that has a specific genetic change (RAS mutation) and has already been treated with one type of chemotherapy. The goal is to see if one combination works better than the other.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
This trial tests a new drug (retlirafusp alfa) combined with two chemotherapy drugs and a targeted therapy (bevacizumab) for people with advanced colorectal cancer that has spread to the liver and has a specific gene change (RAS mutation). It aims to see if this combination can shrink tumors and improve outcomes in people who have not had prior treatment.
This trial tests an experimental drug (HSK42360-Na) combined with standard treatments (cetuximab with or without chemotherapy) for people with advanced colorectal cancer that has a specific BRAF mutation. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
This trial tests a combination of focused radiation (SBRT), chemotherapy (CAPEOX), and two targeted drugs (bevacizumab and an immunotherapy) for colorectal cancer that has spread and can't be removed by surgery. The goal is to see if this combination can shrink tumors and help you live longer.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.